258 related articles for article (PubMed ID: 8769685)
21. Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study). The European Study Group.
Am J Cardiol; 1992 Nov; 70(15):1281-6. PubMed ID: 1442579
[TBL] [Abstract][Full Text] [Related]
22. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.
Steinhagen-Thiessen E
Cardiology; 1994; 85(3-4):244-54. PubMed ID: 7987882
[TBL] [Abstract][Full Text] [Related]
24. Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
Pazzucconi F; Dorigotti F; Gianfranceschi G; Campagnoli G; Sirtori M; Franceschini G; Sirtori CR
Atherosclerosis; 1995 Oct; 117(2):189-98. PubMed ID: 8801864
[TBL] [Abstract][Full Text] [Related]
25. The relation between plasma fibrinogen, blood hematocrit and exercise ST segment depressions in hyperlipoproteinemia.
Olsson AG; Blombäck M; Ekelund LG
Artery; 1980; 7(3):215-23. PubMed ID: 7469795
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)].
Golay A; Lehmann T; James R; Pometta D
Schweiz Med Wochenschr; 1993 Aug; 123(33):1553-8. PubMed ID: 8372340
[TBL] [Abstract][Full Text] [Related]
27. Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial.
Zachoval R; Gerbes AL; Schwandt P; Parhofer KG
J Hepatol; 2001 Jul; 35(1):86-91. PubMed ID: 11495047
[TBL] [Abstract][Full Text] [Related]
28. Effects of simvastatin and pravastatin on peroxidation of erythrocyte plasma membrane lipids in patients with type 2 hypercholesterolemia.
Koter M; Franiak I; Broncel M; Chojnowska-Jezierska J
Can J Physiol Pharmacol; 2003 May; 81(5):485-92. PubMed ID: 12774855
[TBL] [Abstract][Full Text] [Related]
29. Hemorheological and hemodynamic parameters in patients with essential hypertension and their modification by alpha-1 inhibitor drug treatment.
Toth K; Kesmarky G; Vekasi J; Nemes J; Czopf L; Kapronczay P; Halmosi R; Papp E; Juricskay I
Clin Hemorheol Microcirc; 1999; 21(3-4):209-16. PubMed ID: 10711745
[TBL] [Abstract][Full Text] [Related]
30. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
Serajuddin AT; Ranadive SA; Mahoney EM
J Pharm Sci; 1991 Sep; 80(9):830-4. PubMed ID: 1800703
[TBL] [Abstract][Full Text] [Related]
31. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
[TBL] [Abstract][Full Text] [Related]
32. Simvastatin versus pravastatin: efficacy and tolerability in patients with primary hypercholesterolemia.
Malini PL; Ambrosioni E; De Divitiis O; Di Somma S; Rosiello G; Trimarco B
Clin Ther; 1991; 13(4):500-10. PubMed ID: 1934003
[TBL] [Abstract][Full Text] [Related]
33. Lipid-modifying and pleiotropic effects of gemfibrozil, simvastatin and pravastatin in patients with dyslipidemia.
Doncheva NI; Nikolov KV; Vassileva DP
Folia Med (Plovdiv); 2006; 48(3-4):56-61. PubMed ID: 17668698
[TBL] [Abstract][Full Text] [Related]
34. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH
Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069
[TBL] [Abstract][Full Text] [Related]
35. [The whole blood and plasma viscosity changes in course of acute myocardial infarction].
Turczyński B; Słowińska L; Szczesny S; Baschton M; Bartosik-Baschton A; Szyguła J; Wodniecki J; Spyra J
Pol Arch Med Wewn; 2002 Oct; 108(4):971-8. PubMed ID: 12642942
[TBL] [Abstract][Full Text] [Related]
36. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Didangelos TP; Carina MV; Kranitsas DF; Kontopoulos AG
Am J Cardiol; 1997 Sep; 80(5):608-13. PubMed ID: 9294990
[TBL] [Abstract][Full Text] [Related]
38. Effect of hydroxymethylglutaryl-CoA reductase inhibitors on the functional properties of erythrocyte membranes.
Rabini RA; Polenta M; Staffolani R; Tocchini M; Signore R; Testa I; Mazzanti L
Exp Mol Pathol; 1993 Aug; 59(1):51-7. PubMed ID: 8262165
[TBL] [Abstract][Full Text] [Related]
39. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors.
Newman A; Clutterbuck RD; Powles RL; Catovsky D; Millar JL
Leuk Lymphoma; 1997 Feb; 24(5-6):533-7. PubMed ID: 9086443
[TBL] [Abstract][Full Text] [Related]
40. Influence of cholesterol-lowering on plasma membrane lipids and function.
Lijnen P; Echevaría-Vázquez D; Petrov V
Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
